A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901
This study is recruiting at 16 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Inmagene LLC
- Last updated on ClinicalTrials.gov
- August 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Inmagene Site 1 · Lancaster, CA
- Inmagene Site 23 · Los Angeles, CA
Florida · 2
- Inmagene Site 19 · Ocala, FL
- Inmagene Site 4 · Tampa, FL
Illinois · 1
- Inmagene Site 2 · Rolling Meadows, IL
New York · 3
- Inmagene Site 6 · Kew Gardens, NY
- Inmagene Site 21 · New York, NY
- Inmagene Site 11 · Woodbury, NY
North Carolina · 1
- Inmagene Site 20 · Charlotte, NC
North Dakota · 1
- Inmagene Site 10 · Fargo, ND
Ohio · 2
- Inmagene Site 9 · Columbus, OH
- Inmagene Site 5 · Mayfield Heights, OH
Oregon · 1
- Inmagene Site 3 · Portland, OR
South Carolina · 1
- Inmagene Site 12 · Anderson, SC
Texas · 1
- Inmagene Site 8 · Southlake, TX
Washington · 1
- Inmagene Site 7 · Burien, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.